CoChat

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Open access
Chiorean, E. Gabriela, Guthrie, Katherine A., Philip, Philip A., Swisher, Elizabeth M., Jalikis, Florencia, Pishvaian, Michael J., Berlin, Jordan, Noel, Marcus S., Suga, Jennifer M., Garrido-Laguna, Ignacio, Cardin, Dana Backlund, Radke, Marc R., Duong, Mai, Bellasea, Shay, Lowy, Andrew M., Hochster, Howard S. · 2021 · Clinical Cancer Research

Published version of a preprint

Cited by 56

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment with veliparib and mFOLFIRI versus FOLFIRI (control) for metastatic pancreatic cancer. Patients and Methods: This randomized phase II clinical trial led by the SWOG Cancer Research Network enrolled patients between September 1, 2016 and December 13, 2017. The median follow-up was 9 months (IQR 1–27). BRCA1/2 and homologous recombination DNA damage repair (HR-DDR) genetic defects were tested in blood and tumor biopsies. Patients received veliparib 200 mg twice daily, days 1–7 with mFOLFIRI days 3–5, or FOLFIRI in 14-day cycles. Results: After 123 of planned 143 patients were accrued, an interim futility analysis indicated that the veliparib arm was unlikely to be superior to control, and the study was halted. Median overall survival (OS) was 5.4 versus 6.5 months (HR, 1.23; P = 0.28), and median progression-free survival (PFS) was 2.1 versus 2.9 months (HR, 1.39; P = 0.09) with veliparib versus control. Grade 3/4 toxicities were more common with veliparib (69% vs. 58%, P = 0.23). For cancers with HR-DDR defects versus wild-type, median PFS and OS were 7.3 versus 2.5 months (P = 0.05) and 10.1 versus 5.9 months (P = 0.17), respectively, with FOLFIRI, and 2.0 versus 2.1 months (P = 0.62) and 7.4 versus 5.1 months (P = 0.10), respectively, with veliparib plus mFOLFIRI. Conclusions: Veliparib plus mFOLFIRI did not improve survival for metastatic pancreatic cancer. FOLFIRI should be further studied in pancreatic cancers with HR-DDR defects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-1789

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 27

  1. Neuzillet, 2012, FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts, World J Gastroenterol, 18, 4533, 10.3748/wjg.v18.i33.4533 · DOI
  2. Heeke, 2018, Prevalence of homologous recombination-related gene mutations across multiple cancer types, JCO Precis Oncol, 2018, PO.17.00286
  3. Ray Chaudhuri, 2012, Topoisomerase I poisoning results in PARP-mediated replication fork reversal, Nat Struct Mol Biol, 19, 417, 10.1038/nsmb.2258 · DOI · Paper page
  4. Smith, 2005, The novel poly (ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks, Clin Cancer Res, 11, 8449, 10.1158/1078-0432.CCR-05-1224 · DOI
  5. Davidson, 2013, The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines, Invest New Drugs, 31, 461, 10.1007/s10637-012-9886-7 · DOI
  6. Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
  7. Lowery, 2018, Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma, Eur J Cancer, 89, 19, 10.1016/j.ejca.2017.11.004 · DOI
  8. Shroff, 2018, Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation, JCO Precis Oncol, 2018, PO.17.00316
  9. Ahn, 2020, Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study, J Clin Oncol, 38, 10.1200/JCO.2020.38.15_suppl.4637 · doi:10.1200/jco.2020.38.15_suppl.4637
  10. Pishvaian, 2020, A phase I/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer, Clin Cancer Res, 26, 5092, 10.1158/1078-0432.CCR-20-1301 · DOI
  11. O'Reilly, 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma, Cancer, 124, 1374, 10.1002/cncr.31218 · DOI
  12. O'Reilly, 2020, Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation, J Clin Oncol, 38, 1378, 10.1200/JCO.19.02931 · DOI · Paper page
  13. Berlin, 2018, A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors, Br J Cancer, 118, 938, 10.1038/s41416-018-0003-3 · DOI
  14. Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 · DOI · Paper page
  15. Norquist, 2018, Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study, Clin Cancer Res, 24, 777, 10.1158/1078-0432.CCR-17-1327 · DOI · Paper page
  16. Nord, 2011, Accurate and exact CNV identification from targeted high-throughput sequence data, BMC Genomics, 12, 184, 10.1186/1471-2164-12-184 · DOI · Paper page
  17. LoRusso, 2016, Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with adanced solid tumors, Clin Cancer Res, 22, 3227, 10.1158/1078-0432.CCR-15-0652 · DOI
  18. Coleman, 2019, Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer, N Engl J Med, 381, 2403, 10.1056/NEJMoa1909707 · DOI · Paper page
  19. Diéras, 2020, Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomized, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 21, 1269, 10.1016/S1470-2045(20)30447-2 · DOI · Paper page
  20. Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 · DOI · Paper page
  21. Golan, 2021, Final overall survival results from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, J Clin Oncol, 39, 10.1200/JCO.2021.39.3_suppl.378 · DOI
  22. Reiss, 2021, Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2, J Clin Oncol, 39, 2497, 10.1200/JCO.21.00003 · DOI · Paper page
  23. Golan, 2021, Genomic features and classification of homologous recombination–deficient pancreatic ductal adenocarcinoma, Gastroenterology, 160, 2119, 10.1053/j.gastro.2021.01.220 · DOI
  24. Chung, 2021, Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001, J Clin Oncol, 39, 10.1200/JCO.2021.39.3_suppl.TPS447 · doi:10.1200/jco.2021.39.3_suppl.tps447
  25. Yap, 2020, Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2- and non-BRCA1/2-mutant cancers, Cancer Discov, 10, 1528, 10.1158/2159-8290.CD-20-0163 · DOI
  26. Prasanna, 2018, Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy, Cancer Sci, 109, 3383, 10.1111/cas.13799 · DOI
  27. Zheng-Lin, 2021, Pancreatic ductal adenocarcinoma in the era of precision medicine, Semin Oncol, 10.1053/j.seminoncol.2021.01.005 · DOI

Cited by

See all 56

Metadata

Authors
Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F., Pishvaian, M. J., Berlin, J., Noel, M. S., Suga, J. M., Garrido-Laguna, I., Cardin, D. B., Radke, M. R., Duong, M., Bellasea, S., Lowy, A. M., & Hochster, H. S.
Venue
Clinical Cancer Research
Published
2021-12-01
Volume
27
Issue
23
Pages
6314-6322
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3204487449
Cited by
56
References
9
FWCI
3.02
Type
journal article
Language
en
Open access
bronze
Funders
National Institutes of Health (CA180888, CA180819, CA180820, CA180821, CA233230, CA189821, CA180818, CA189830, CA189856, CA189858, CA180826, CA190002, CA189957, CA180828, CA189971, CA180835, CA189809, CA46368, CA189960, CA180834, CA239767, CA189860, CA189861, CA189854, CA189872, CA189958, CA180801, CA189848)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1789
The paper
Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F., Pishvaian, M. J., Berlin, J., Noel, M. S., Suga, J. M., Garrido-Laguna, I., Cardin, D. B., Radke, M. R., Duong, M., Bellasea, S., Lowy, A. M., & Hochster, H. S. (2021). Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.